Panel Discussion: Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology

2:10 pm - Wednesday 7th October 2026

  • Tumor heterogeneity determines treatment response and resistance, and AI-powered computational pathology makes heterogeneity tractable for drug development
  • Tissue analysis succeeds in drug development when scientific, computational, and delivery expertise are integrated from the start, not assembled project by project
  • Connecting imaging features to outcomes to generate predictive biomarkers, and translation into cross-cohort and cross-platform validation and deployment
  • Infrastructure and global access shape which biomarkers can actually reach patients. H&E-based approaches can have an important role in ensuring equitable, global CDx access

Speakers:

Sarah Hersey
Vice President & Head, Precision Medicine, Translational Sciences & Bioanalytical
Bristol Myers Squibb
Grainger Greene
Head, Product
Nucleai
Ben Withey
Director, Commercial Diagnostics, CDx Lead
Pfizer
Lauri Diehl
Executive Director, Research Pathology
Gilead Sciences
Sizun Jiang
Assistant Professor
Harvard Medical School & Beth Israel Deaconess Medical Center